Angehefteter Tweet

📊 New ALS Survival Data
90% of #ALS participants in EAP for NurOwn® survived over 5 years, compared to the typical 10% survival rate. These real-world findings support the scientific rationale for the upcoming Phase 3b trial under FDA SPA. Read here: bit.ly/45pT73n

English
















